UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000010869 |
|---|---|
| Receipt number | R000012560 |
| Scientific Title | Phase II trial of trasutuzumab plus docetaxel for previous trastuzumab treated unresectable or recurrent HER2 positive gastric cancer (T-CORE1203) |
| Date of disclosure of the study information | 2013/06/06 |
| Last modified on | 2020/07/07 15:22:31 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2013/06/04 15:33:16 | ||
| 2 | Update | 2013/12/05 12:45:38 | TEL Last name of contact person Last name of contact person |
|
| 3 | Update | 2014/12/05 08:56:15 | Anticipated trial start date |
|
| 4 | Update | 2014/12/05 08:57:06 | Anticipated trial start date |
|
| 5 | Update | 2015/12/10 14:39:49 | Anticipated trial start date |
|
| 6 | Update | 2016/01/05 09:21:32 | Email |
|
| 7 | Update | 2016/12/06 13:47:18 | Recruitment status |
|
| 8 | Update | 2019/02/18 15:15:20 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Address Address TEL Last name of contact person Last name of contact person Name of primary person or sponsor Institute Organization Organization Organization1 Address1 Tel1 Email1 |
|
| 9 | Update | 2020/07/07 14:09:38 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 10 | Update | 2020/07/07 14:11:19 | Number of participants that the trial has enrolled |
|
| 11 | Update | 2020/07/07 15:22:31 | Recruitment status Date of IRB Last follow-up date |
